BeOne Medicines Ltd. (ONC) Q3 2026 Earnings Call

Concluded Nov 5, 2026

Nov 5, 2026

Revenue $1.89B +33.8% YoY

Diluted EPS $0.25 +212.5% YoY

Gross margin 88.5% +2.4 pp YoY

Net income $384.71M +208.2% YoY

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 5, 2026: BeOne Medicines Ltd. reported third-quarter total global revenues of $1.9 billion, up 34% from the prior year, and BRUKINSA (zanubrutinib) revenues of $1.4 billion, up 34%. It raised 2026 total revenue guidance to $6.9 to $7.0 billion.
10-Q report · filed Nov 5, 2026: BeOne Medicines Ltd. reported third quarter 2026 total global revenues of $1.9 billion, up 34% versus third quarter 2025, as BRUKINSA revenue reached $1.4 billion, also up 34%. Diluted GAAP earnings per ADS were $3.28 and non-GAAP diluted earnings per ADS were $4.59.

The audio replay and transcript follow the call.

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Open the source you need; every reader stays inside this workspace.

Presentation 12 pages 8-K earnings release Filed Nov 5, 2026 10-Q report Filed Nov 5, 2026 Company webcastOpen the original investor-relations page

How the reported period landed and where the business moved.

United States$1.03B +36.2% YoY

China$536.37M +21.9% YoY

Europe$239.56M +43.8% YoY

All Other Countries Except The United States Of America China And Europe$85.98M +68.7% YoY